<SEC-DOCUMENT>0001096906-24-000127.txt : 20240130
<SEC-HEADER>0001096906-24-000127.hdr.sgml : 20240130
<ACCEPTANCE-DATETIME>20240130145356
ACCESSION NUMBER:		0001096906-24-000127
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20240130
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240130
DATE AS OF CHANGE:		20240130

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UTAH MEDICAL PRODUCTS INC
		CENTRAL INDEX KEY:			0000706698
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				870342734
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12575
		FILM NUMBER:		24577568

	BUSINESS ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84047
		BUSINESS PHONE:		8015661200
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>utmd-20240130.htm
<DESCRIPTION>UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:i="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<head>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK5GW761L0VDHRHPYZ]. www.edgarsuite.com -->
<title>UTAH MEDICAL PRODUCTS, INC. - Form 8-K SEC filing</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body>
<div style="display:none">
<ix:header>
<ix:hidden>
<ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="D240130" id="fact1">0000706698</ix:nonNumeric>
<ix:nonNumeric name="dei:AmendmentFlag" contextRef="D240130" id="fact2">false</ix:nonNumeric>
</ix:hidden>
<ix:references>
<link:schemaRef xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="utmd-20240130.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<i:context id="D240130">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2024-01-30</i:startDate>
<i:endDate>2024-01-30</i:endDate>
</i:period>
</i:context>
</ix:resources>
</ix:header>
</div>
<div style="margin-left:72pt;width:468pt"><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:14pt stHtmlOvrFontNm;margin:0;text-align:center"><b>UNITED STATES </b></p>
<p style="font:14pt stHtmlOvrFontNm;margin:0;text-align:center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style="font:15pt stHtmlOvrFontNm;margin:0;text-align:center"><b>Washington, D.C. &#160;20549</b></p>
<p style="font:15pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
<p style="font:14pt stHtmlOvrFontNm;margin:0;text-align:center"><b>FORM <ix:nonNumeric name="dei:DocumentType" contextRef="D240130" escape="true" id="ixv-349">8-K</ix:nonNumeric></b></p>
<p style="font:14pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
<p style="font:14pt stHtmlOvrFontNm;margin:0;text-align:center"><b>CURRENT REPORT</b></p>
<p style="font:14pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
<p style="font:12pt stHtmlOvrFontNm;margin:0;text-align:center"><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p>
<p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
<p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:center">Date of Report (date of earliest event reported): &#160;<b><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="D240130" format="ixt:datemonthdayyearen" id="ixv-350">January 30, 2024</ix:nonNumeric></b></p>
<p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
<p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:14pt stHtmlOvrFontNm;margin:0;text-align:center"><b><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="D240130" escape="true" id="ixv-351">UTAH MEDICAL PRODUCTS, INC.</ix:nonNumeric></b></p>
</td></tr>
<tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">(Exact name of registrant as specified in its charter)</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.6%"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:center"><span style="font-size:11pt"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="D240130" format="ixt-sec:stateprovnameen" id="ixv-352">Utah</ix:nonNumeric></b></span></p>
</td><td valign="top" style="width:2.6%"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:center"><span style="font-size:11pt"><b><ix:nonNumeric name="dei:EntityFileNumber" contextRef="D240130" escape="true" id="ixv-353">000-12575</ix:nonNumeric></b></span></p>
</td><td valign="top" style="width:2.58%"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:center"><span style="font-size:11pt"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="D240130" escape="true" id="ixv-354">87-0342734</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">(State or other jurisdiction of</p>
</td><td valign="top" style="width:2.6%"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">(Commission File Number)</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">(IRS Employer</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">incorporation or organization)</p>
</td><td valign="top" style="width:2.6%"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">Identification No.)</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.6%"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:center"><span style="font-size:12pt"><b><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="D240130" escape="true" id="ixv-355">7043 South 300 West</ix:nonNumeric></b></span></p>
</td><td valign="top" style="width:2.58%"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:center"><span style="font-size:12pt"><b><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="D240130" escape="true" id="ixv-356">Midvale</ix:nonNumeric></b><b>, </b><b><ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="D240130" format="ixt-sec:stateprovnameen" id="ixv-357">Utah</ix:nonNumeric></b></span></p>
</td><td valign="top" style="width:2.58%"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:center"><span style="font-size:12pt"><b><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="D240130" escape="true" id="ixv-358">84047</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">(Address of principal executive offices)</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">(Zip code)</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:11pt stHtmlOvrFontNm;margin:0">Registrant&#8217;s telephone number, including area code: &#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:center"><span style="font-size:12pt"><b>Phone: </b><b>(</b><b><ix:nonNumeric name="dei:CityAreaCode" contextRef="D240130" escape="true" id="ixv-359">801</ix:nonNumeric></b><b>) </b><b><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="D240130" escape="true" id="ixv-360">566-1200</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:12pt stHtmlOvrFontNm;margin:0;text-align:center"><b>n/a</b></p>
</td></tr>
<tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">(Former name or former address, if changed since last report)</p>
</td></tr>
</table>
<p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
<p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>
<p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse"><tr><td valign="top" style="width:27.9pt"><p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:justify"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="D240130" format="ixt-sec:boolballotbox" id="ixv-361">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:justify"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="D240130" format="ixt-sec:boolballotbox" id="ixv-362">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:justify"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="D240130" format="ixt-sec:boolballotbox" id="ixv-363">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:justify"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="D240130" format="ixt-sec:boolballotbox" id="ixv-364">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td colspan="2" valign="top" style="width:478.8pt"><p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:justify">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:right">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="D240130" format="ixt-sec:boolballotbox" id="ixv-365">&#9744;</ix:nonNumeric></p>
</td></tr>
<tr><td colspan="2" valign="top" style="width:478.8pt"><p style="font:10pt stHtmlOvrFontNm;margin:0">&#160;</p>
</td></tr>
<tr><td colspan="2" valign="top" style="width:478.8pt"><p style="font:10pt stHtmlOvrFontNm;margin:0">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&#160;&#160;]</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:11pt stHtmlOvrFontNm;margin:0"><b>ITEM 2.02&#8212;RESULTS OF OPERATIONS AND FINANCIAL CONDITION</b></p>
<p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
<p style="font:12pt stHtmlOvrFontNm;margin:0;margin-left:72pt">Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three and twelve months ended December 31, 2023 and forward-looking statements relating to 2023 and beyond as presented in a press release dated January 30, 2024. &#160;</p>
<p style="font:12pt stHtmlOvrFontNm;margin:0;margin-left:72pt">&#160;</p>
<p style="font:12pt stHtmlOvrFontNm;margin:0;margin-left:72pt">The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.</p>
<p style="font:12pt stHtmlOvrFontNm;margin:0;margin-left:90pt">&#160;</p>
<p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
<p style="font:11pt stHtmlOvrFontNm;margin:0"><b>ITEM 9.01&#8212;FINANCIAL STATEMENTS AND EXHIBITS</b></p>
<p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
<p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">The following is filed as an exhibit to this report: &#160;</p>
<p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:12.56%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center"><b>Exhibit</b></p>
<p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center"><b>Number*</b></p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:69.22%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
<p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center"><b>Title of Document</b></p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:12.98%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
<p style="font:9pt stHtmlOvrFontNm;margin:0;text-align:center"><b>Location</b></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:12.56%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:center"><b>Item 99.1</b></p>
</td><td valign="top" style="background-color:#CCEEFF;width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:69.22%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify"><span style="font-size:12pt;color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex99z1.htm" style="text-decoration:none">Financial information for Utah Medical Prod</a><a href="utmd_ex99z1.htm" style="text-decoration:none">ucts, Inc. for the three and twelve months ended December 31</a><a href="utmd_ex99z1.htm" style="text-decoration:none">, 2023 and forward-looking statements relating to 2023 and beyond as present</a><a href="utmd_ex99z1.htm" style="text-decoration:none">ed in a press release dated January 30, 2024</a><a href="utmd_ex99z1.htm" style="text-decoration:none">.</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.98%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:12.56%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:69.22%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt stHtmlOvrFontNm;margin:0">&#160;</p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:12.98%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">This filing</p>
</td></tr>
</table>
<p style="font:11pt stHtmlOvrFontNm;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">&#160;</p>
<p style="font:11pt stHtmlOvrFontNm;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">_______________________________________</p>
<p style="font:9pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt;margin-left:18pt;text-align:justify"><kbd style="position:absolute;font:9pt stHtmlOvrFontNm;margin-left:-18pt">*</kbd>All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document. &#160;</p>
<p style="font:11pt stHtmlOvrFontNm;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">&#160;</p>
<p style="font:11pt stHtmlOvrFontNm;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">&#160;</p>
<p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:center"><b>SIGNATURES</b></p>
<p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
<p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse"><tr><td valign="top" style="width:234.05pt"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify"><b>UTAH MEDICAL PRODUCTS, INC.</b></p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">Dated:  January 30, 2024</p>
</td><td valign="top" style="width:26.7pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">By:</p>
</td><td valign="top" style="width:218.05pt;border-bottom:0.5pt solid #000000"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">/s/ Kevin L. Cornwell</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:26.7pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:218.05pt;border-top:0.5pt solid #000000"><p style="font:11pt stHtmlOvrFontNm;margin:0;text-align:justify">Kevin L. Cornwell, Chief Executive Officer</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/></div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>utmd_ex99z1.htm
<DESCRIPTION>FINANCIAL INFORMATION
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK5GW761L0VDHRHPYZ]. www.edgarsuite.com -->
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'><B>EXHIBIT 99.1</B></P>
<P align=center style='font:10pt stHtmlOvrFontNm;margin:0;margin-right:-6.5pt'>&nbsp;</P>
<P align=center style='font:10pt stHtmlOvrFontNm;margin:0;margin-right:-6.5pt'><B>UTMD Reports Audited Year 2023 and Fourth Quarter Financial Performance</B></P>
<P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:0pt'>Contact: Brian Koopman (801) 566-1200</KBD><KBD style=margin-left:360pt></KBD>January 30, 2024&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>Salt Lake City, Utah &#8211;&nbsp;With Revenues 4% lower and Net Income and Earnings Per Share 1% higher than in 2022, Utah Medical Products, Inc. (Nasdaq: UTMD) achieved financial results for the full year of 2023 consistent with management&#8217;s beginning of year projections. &nbsp;&nbsp;&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; &#163;&nbsp;or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and &#8364;&nbsp;or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted. &nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>Overview of Results</FONT></P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>A summary comparison of 4Q and calendar year 2023 income statement measures with the same periods of 2022 follows:</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:198pt'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4Q</KBD><KBD style=margin-left:270pt></KBD> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Year&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>2023 to 2022 Comparison</FONT> &nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;<FONT style='border-bottom:1px solid #000000'>(October&#8211;December)</FONT> &nbsp;&nbsp;&nbsp;&nbsp;<FONT style='border-bottom:1px solid #000000'>(January-December)</FONT></P>
<TABLE style=border-collapse:collapse;width:499.5pt;margin-left:27.9pt><TR><TD valign=top style=width:166.5pt><P style='font:11pt stHtmlOvrFontNm;margin:0;margin-right:-6.3pt'>Revenues (Sales):</P>
</TD><TD valign=top style=width:117pt><P style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:30.6pt;margin-right:-6.3pt'> &nbsp;&nbsp;&nbsp;( &nbsp;9%)</P>
</TD><TD valign=top style=width:99pt><P style='font:11pt stHtmlOvrFontNm;margin:0;margin-right:-6.3pt'> &nbsp;&nbsp;&nbsp;( &nbsp;4%)</P>
</TD><TD valign=top style=width:117pt><P style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:17.1pt;margin-right:-6.3pt'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:166.5pt><P style='font:11pt stHtmlOvrFontNm;margin:0;margin-right:-6.3pt'>Gross Profit (GP):</P>
</TD><TD valign=top style=width:117pt><P style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:30.6pt;margin-right:-6.3pt'> &nbsp;&nbsp;&nbsp;(15%)</P>
</TD><TD valign=top style=width:99pt><P style='font:11pt stHtmlOvrFontNm;margin:0;margin-right:-6.3pt'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(7%)</P>
</TD><TD valign=top style=width:117pt><P style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:17.1pt;margin-right:-6.3pt'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:166.5pt><P style='font:11pt stHtmlOvrFontNm;margin:0;margin-right:-6.3pt'>Operating Income (OI):</P>
</TD><TD valign=top style=width:117pt><P style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:30.6pt;margin-right:-6.3pt'> &nbsp;&nbsp;&nbsp;(22%) </P>
</TD><TD valign=top style=width:99pt><P style='font:11pt stHtmlOvrFontNm;margin:0;margin-right:-6.3pt'> &nbsp;&nbsp;&nbsp;(15%) </P>
</TD><TD valign=top style=width:117pt><P style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:17.1pt;margin-right:-6.3pt'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:166.5pt><P style='font:11pt stHtmlOvrFontNm;margin:0;margin-right:-6.3pt'>Income Before Tax (EBT):</P>
</TD><TD valign=top style=width:117pt><P style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:30.6pt;margin-right:-6.3pt'> &nbsp;&nbsp;&nbsp;(10%)</P>
</TD><TD valign=top style=width:99pt><P style='font:11pt stHtmlOvrFontNm;margin:0;margin-right:-6.3pt'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3%) </P>
</TD><TD valign=top style=width:117pt><P style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:17.1pt;margin-right:-6.3pt'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:166.5pt><P style='font:11pt stHtmlOvrFontNm;margin:0;margin-right:-6.3pt'>Net Income (NI):</P>
</TD><TD valign=top style=width:117pt><P style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:30.6pt;margin-right:-6.3pt'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6%)</P>
</TD><TD valign=top style=width:99pt><P style='font:11pt stHtmlOvrFontNm;margin:0;margin-right:-6.3pt'> &nbsp;+ &nbsp;&nbsp;1%</P>
</TD><TD valign=top style=width:117pt><P style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:17.1pt;margin-right:-6.3pt'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:166.5pt><P style='font:11pt stHtmlOvrFontNm;margin:0;margin-right:-6.3pt'>Earnings Per Share (EPS):</P>
</TD><TD valign=top style=width:117pt><P style='font:11pt stHtmlOvrFontNm;margin-top:0pt;margin-bottom:6pt;text-indent:30.6pt;margin-right:-6.5pt'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6%)</P>
</TD><TD valign=top style=width:99pt><P style='font:11pt stHtmlOvrFontNm;margin-top:0pt;margin-bottom:6pt;margin-right:-6.5pt'> &nbsp;+ &nbsp;&nbsp;1%</P>
</TD><TD valign=top style=width:117pt><P style='font:11pt stHtmlOvrFontNm;margin-top:0pt;margin-bottom:6pt;text-indent:17.1pt;margin-right:-6.5pt'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>Profit margins in 4Q and year 2023 compared to 4Q and year 2022 follow:</P>
<TABLE style=border-collapse:collapse;width:461.6pt;margin-left:-1.7pt><TR><TD valign=top style=width:191.6pt><P style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>&nbsp;</P>
</TD><TD valign=top style=width:67.5pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>4Q 2023 </P>
<P align=center style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:7.1pt;margin-right:-6.3pt'><FONT style='border-bottom:1px solid #000000'>(Oct &#8211;&nbsp;Dec)</FONT></P>
</TD><TD valign=top style='width:76.5pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:7.1pt;margin-right:-6.5pt'>4Q 2022</P>
<P align=center style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:7.1pt;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>(Oct-Dec)</FONT></P>
</TD><TD valign=top style='width:66.7pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:7.1pt;margin-right:-6.5pt'>2023</P>
<P align=center style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:7.1pt;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>(Jan&#8211;Dec)</FONT></P>
</TD><TD valign=top style=width:59.3pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:7.1pt;margin-right:-6.5pt'>2022</P>
<P align=center style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:7.1pt;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>(Jan&#8211;Dec)</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:191.6pt><P style='font:11pt stHtmlOvrFontNm;margin:0;margin-right:-6.3pt'>Gross Profit Margin (GP/ sales):</P>
</TD><TD valign=top style=width:67.5pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>57.6%</P>
</TD><TD valign=top style='width:76.5pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>61.3% </P>
</TD><TD valign=top style='width:66.7pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>59.8%</P>
</TD><TD valign=top style=width:59.3pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>61.6%</P>
</TD></TR>
<TR><TD valign=top style=width:191.6pt><P style='font:11pt stHtmlOvrFontNm;margin:0;margin-right:-6.3pt'>Operating Income Margin (OI/ sales):</P>
</TD><TD valign=top style=width:67.5pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>32.0%</P>
</TD><TD valign=top style='width:76.5pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>37.3%</P>
</TD><TD valign=top style='width:66.7pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>33.4%</P>
</TD><TD valign=top style=width:59.3pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>37.9%</P>
</TD></TR>
<TR><TD valign=top style=width:191.6pt><P style='font:11pt stHtmlOvrFontNm;margin:0;margin-right:-6.3pt'>Income Before Tax Margin (EBT/ sales):</P>
</TD><TD valign=top style=width:67.5pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>40.7%</P>
</TD><TD valign=top style='width:76.5pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>41.2%</P>
</TD><TD valign=top style='width:66.7pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>40.0%</P>
</TD><TD valign=top style=width:59.3pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>39.5%</P>
</TD></TR>
<TR><TD valign=top style=width:191.6pt><P style='font:11pt stHtmlOvrFontNm;margin:0;margin-right:-6.3pt'>Net Income Margin (NI/ sales):</P>
</TD><TD valign=top style=width:67.5pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>34.8%</P>
</TD><TD valign=top style='width:76.5pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>33.6%</P>
</TD><TD valign=top style='width:66.7pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>33.1%</P>
</TD><TD valign=top style=width:59.3pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>31.5%</P>
</TD></TR>
</TABLE>
<P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>Total consolidated worldwide sales were $2 million (4%) lower in 2023 because, as expected, sales to UTMD&#8217;s biopharma OEM customer were $3 million lower. &nbsp;With lower Sales together with higher overhead costs associated primarily with cost-of-living adjustments for employees, and inflation in raw material costs, UTMD was not able to maintain GP margins in 2023 consistent with 2022, although the result was near its targeted 60% level for the year. OI margins were further diluted by unusual litigation expense associated with Filshie clip product liability lawsuits in the U.S. On the other hand, with the help of interest income on UTMD&#8217;s cash balances, EBT and NI margins were higher in 2023 than in 2022, allowing an increase in NI and EPS for the year.</P>
<P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>Worldwide (WW) consolidated sales in 2023 were $2,057 lower than in 2022, essentially because sales to UTMD&#8217;s largest biopharma OEM customer were $2,925 lower. Overall domestic sales in 2023 were down 12% while outside the U.S. (OUS) sales were up 8%. Although sales invoiced in foreign currencies were 15% higher in 2023 compared to 2022, making up 30% of 2023 total consolidated sales compared to just 25% in 2022, foreign currency exchange (FX) rate changes had a minimal impact.</P>
<P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>UTMD&#8217;s December 31, 2023 Balance Sheet, in the continued absence of debt, remained strong. After using $4,282 cash to pay stockholder dividends and $639 for new manufacturing equipment and tooling during 2023, ending Cash and Investments were $92.9 million on December 31, 2023 compared to $75.1 million on December 31, 2022. In addition, in order to hedge against ongoing supply chain disruption, UTMD continued to use its cash trove to increase inventories $0.8 million, a 9% increase from the end of </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'><FONT style=font-size:11pt>2022 despite 4% lower revenues. Stockholders&#8217; Equity (SE) increased $14.1 million as of December 31, 2023 from December 31, 2022 despite the fact that stockholder dividends reduced SE. </FONT></P>
<P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>Foreign currency exchange (FX) rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of calendar year 2023 compared to the end of 2022 and the end of 3Q 2023 follow:</P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:78.6pt><P style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:52.8pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>12-31-23</FONT></P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>12-31-22</FONT></P>
</TD><TD valign=top style='width:67.5pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD><TD valign=top style='width:58.5pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>9-30-23</FONT></P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:78.6pt><P style='font:11pt stHtmlOvrFontNm;margin:0'>GBP</P>
</TD><TD valign=top style=width:52.8pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>1.27386</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>1.20771</P>
</TD><TD valign=top style='width:67.5pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'> &nbsp;5.5%</P>
</TD><TD valign=top style='width:58.5pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>1.22134</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'> 4.3%</P>
</TD></TR>
<TR><TD valign=top style=width:78.6pt><P style='font:11pt stHtmlOvrFontNm;margin:0'>EUR</P>
</TD><TD valign=top style=width:52.8pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>1.10593</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>1.06940</P>
</TD><TD valign=top style='width:67.5pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'> &nbsp;3.4%</P>
</TD><TD valign=top style='width:58.5pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>1.05841</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'> 4.5%</P>
</TD></TR>
<TR><TD valign=top style=width:78.6pt><P style='font:11pt stHtmlOvrFontNm;margin:0'>AUD</P>
</TD><TD valign=top style=width:52.8pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>0.68248</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>0.68050</P>
</TD><TD valign=top style='width:67.5pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'> &nbsp;0.3%</P>
</TD><TD valign=top style='width:58.5pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>0.64494</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'> 5.8%</P>
</TD></TR>
<TR><TD valign=top style=width:78.6pt><P style='font:11pt stHtmlOvrFontNm;margin:0'>CAD</P>
</TD><TD valign=top style=width:52.8pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>0.75733</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>0.73899</P>
</TD><TD valign=top style='width:67.5pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'> &nbsp;2.5%</P>
</TD><TD valign=top style='width:58.5pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>0.73873</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'> 2.5%</P>
</TD></TR>
</TABLE>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>Revenues (sales)</FONT> - <FONT style='border-bottom:1px solid #000000'>4Q 2023</FONT></P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>Total consolidated 4Q 2023 UTMD worldwide (WW) sales were $12,333 compared to $13,575 in 4Q 2022, $1,242 (9.1%) lower than in 4Q 2022. Total constant currency sales were $1,441 (10.6%) lower. U.S. domestic sales were 10.7% lower and OUS sales were 7.2% lower in USD terms than in 4Q 2022.  </P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>Domestic U.S. sales in 4Q 2023 were $6,736 compared to $7,542 in 4Q 2022. &nbsp;Domestic sales are invoiced in USD and are not subject to FX rate fluctuations. The components of domestic sales include 1) &#8220;direct other device sales&#8221; of UTMD&#8217;s medical devices to user facilities (and med/surg stocking distributors for hospitals), excluding Filshie device sales, 2) &#8220;OEM sales&#8221; of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) &#8220;direct Filshie device sales&#8221;. UTMD separates Filshie device sales from other medical device sales direct to medical facilities because of their significance, and the acquisition history. Direct non-Filshie device sales, representing 53% of total domestic sales, were $170 (4.5%) lower in 4Q 2023 than in 4Q 2022. OEM sales, representing 29% of total domestic sales, were $520 (21.1%) lower. Direct Filshie device sales, representing 18% of total domestic sales, were $117 (8.9%) lower in 4Q 2023 compared to 4Q 2022. &nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>OUS sales in 4Q 2023 were $5,597 compared to $6,033 in 4Q 2022. Unlike earlier in the year when the USD was stronger, the FX rate impact on OUS sales of a stronger EUR and GBP added $199 to 4Q 2023 sales relative to a 4Q 2022 constant currency basis. This is evidence that results for any given three-month period in comparison with a previous three-month period may not be indicative of comparative results for the year as a whole.  &#8220;Constant currency&#8221; means exchanging foreign currency sales into USD-denominated sales at the same FX rate as was in the previous period of time being compared. FX rates for income statement purposes are transaction-weighted averages. The average FX rates from the applicable foreign currency to USD during 4Q 2023 and 4Q 2022 for revenue purposes follow:</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:180pt'><FONT style='border-bottom:1px solid #000000'>4Q 2023</FONT></KBD><KBD style=margin-left:248.1pt></KBD><FONT style='border-bottom:1px solid #000000'>4Q 2022</FONT> &nbsp;&nbsp;&nbsp;<FONT style='border-bottom:1px solid #000000'>Change</FONT>&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:108pt'>GBP</KBD><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:180pt'>  1.2411</KBD><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:248.1pt'>  1.1788</KBD><KBD style=margin-left:297.7pt></KBD>+ &nbsp;5.3%&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:108pt'>EUR</KBD><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:180pt'>  1.0857</KBD><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:248.1pt'>  1.0192</KBD><KBD style=margin-left:297.7pt></KBD>+ &nbsp;6.5%&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:108pt'>AUD</KBD><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:180pt'>  0.6509</KBD><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:248.1pt'>  0.6530</KBD><KBD style=margin-left:297.7pt></KBD> &nbsp;( 0.3%)&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:108pt'>CAD</KBD><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:180pt'>  0.7339</KBD><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:248.1pt'>  0.7361</KBD><KBD style=margin-left:297.7pt></KBD> &nbsp;( 0.3%)&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>The combined weighted-average positive FX impact on 4Q 2023 foreign currency sales was 5.3%. &nbsp;The portion of OUS sales invoiced in foreign currencies in USD terms were 32% of total consolidated 4Q 2023 sales compared to 27% in 4Q 2022. &nbsp;&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>OUS sales invoiced in foreign currencies are to direct end-users in Ireland, the UK, France, Canada, Australia and New Zealand, and to OUS distributors of products manufactured by UTMD subsidiaries in Ireland and the UK. &nbsp;In USD terms, export sales to OUS distributors from Ireland represented 67% of total OUS distributor sales. Export sales from the U.S. to OUS distributors are invoiced in USD. &nbsp;Sales to OUS distributors were 12% lower in 4Q 2023 than in 4Q 2022 due mainly to lower Ireland biopharma OEM shipments. Direct to end-user OUS shipments are generally invoiced in the applicable local </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'><FONT style=font-size:11pt>currency. &nbsp;Helped by an approximate 6% stronger GBP and EUR, direct to end-user OUS 4Q 2023 sales in USD terms were 40% higher in Ireland and 19% higher in the UK. &nbsp;On the other hand, direct to end-user sales in USD terms were 17% lower in Canada, 13% lower in Australia/New Zealand and 1% lower in France, compared to 4Q 2022. &nbsp;The FX rates in Canada and Australia/New Zealand were about the same in both periods. </FONT></P>
<P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Sales</FONT> -<FONT style='border-bottom:1px solid #000000'>2023 Year</FONT></P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>Total consolidated 2023 UTMD WW USD-denominated sales were $50,224 compared to $52,281 in 2022, which was $2,057 (3.9%) lower than in 2022. The decline essentially resulted from the fact that 2023 WW shipments by UTMD to its largest OEM customer were $2,925 (25%) lower, which was anticipated in the Company&#8217;s beginning-of-year projections. U.S. domestic sales were 12% lower and OUS USD-denominated sales were 8% higher than in 2022.   </P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>Domestic U.S. sales in 2023 were $28,204 compared to $31,971 in 2022, which was $3,767 (11.8%) lower than in 2022. All three categories of domestic sales were lower, led by U.S. OEM sales which were $2,438 (22.4%) lower than in 2022. &nbsp;Domestic sales to UTMD&#8217;s biopharma OEM customer were $2,581 (28.7%) lower. This trend is expected to continue in 2024. &nbsp;Domestic Filshie device sales, representing 17% of total domestic sales, were $470 (9.0%) lower in 2023 compared to 2022. Direct device sales other than Filshie, representing 53% of total domestic sales, were $859 (5.4%) lower in 2023 than in 2022. In this last category, domestic neonatal device sales alone were $866 lower, predominantly in 2Q 2023 as a result of continued raw materials supply chain disruption. </P>
<P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>OUS USD-denominated sales in 2023 were $1,710 (+8.4%) higher at $22,020 compared to $20,310 in 2022. Sales invoiced in foreign currencies, which were $14,871 when converted to USD, represented 68% of OUS sales and 30% of consolidated total sales. A slightly weaker USD added $166 in OUS foreign currency sales compared to constant currency terms. &nbsp;FX rates for income statement purposes are transaction-weighted averages. The weighted-average FX rates from the applicable foreign currency to USD during 2023 and 2022 for revenue purposes follow:</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:180pt'><FONT style='border-bottom:1px solid #000000'> 2023</FONT></KBD><KBD style=margin-left:248.1pt></KBD><FONT style='border-bottom:1px solid #000000'> 2022</FONT> &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;<FONT style='border-bottom:1px solid #000000'>Change</FONT>&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:108pt'>GBP</KBD><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:180pt'> 1.2428</KBD><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:248.1pt'> 1.2287</KBD><KBD style=margin-left:297.7pt></KBD> + 1.2%&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:108pt'>EUR</KBD><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:180pt'> 1.0808</KBD><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:248.1pt'> 1.0520</KBD><KBD style=margin-left:297.7pt></KBD> + 2.7%&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:108pt'>AUD</KBD><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:180pt'> 0.6660</KBD><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:248.1pt'> 0.6932</KBD><KBD style=margin-left:297.7pt></KBD> &nbsp;( 3.9%)&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:108pt'>CAD</KBD><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:180pt'> 0.7409</KBD><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:248.1pt'> 0.7683</KBD><KBD style=margin-left:297.7pt></KBD> &nbsp;( 3.6%)&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>The combined weighted-average favorable FX impact on 2023 foreign currency OUS sales was 1.1%, increasing reported USD sales by $166 relative to the same foreign currency sales in 2022. &nbsp;In constant currency terms, OUS sales in 2023 were 4.3% lower than OUS sales in 2022. The portion of OUS sales invoiced in foreign currencies in USD terms was 30% of total consolidated 2023 USD sales compared to 25% in 2022. Including the impact of changed FX rates, OUS 2023 direct to end-user sales in USD terms were 14% higher in Ireland, 15% lower in Canada, 7% higher in France and 21% higher in the UK. Direct to end-user sales in Australia, which included New Zealand, were 17% lower. USD denominated sales to OUS distributors were 11% higher in 2023 than in 2022. </P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>Gross Profit (GP)</FONT> &nbsp;&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>GP results from subtracting the costs of manufacturing, quality assurance and receiving materials from suppliers. UTMD&#8217;s GP was $2,158 (6.7%) lower in 2023 than in 2022, and $1,229 (14.8%) lower in 4Q 2023 than in 4Q 2022. UTMD generally did not increase prices since February 2023, except on a specific basis for custom OEM work. But supplier costs for raw materials continued to increase and the Company implemented further cost-of-living adjustments during 2023 for employees. UTMD expects further dilution of its GP margin in 2024 as biopharma OEM sales are projected to decline significantly without a comparable decline in fixed manufacturing overheads. &nbsp;&nbsp;&nbsp; &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>Operating Income (OI)</FONT> </P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>OI results from subtracting Operating Expenses (OE) from GP. For the year 2023, OI was $16,777 compared to $19,790 in 2022, a 15.2% decrease. &nbsp;The $3,012 decrease in OI was from a combination of $2,158 lower GP and $854 higher OE. &nbsp;OI in 4Q 2023 was $3,944 compared to $5,070 in 4Q 2022. &nbsp;The $1,126 lower 4Q 2023 OI was a combination of $1,229 lower GP and $103 lower OE. &nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>OE are comprised of Sales and Marketing (S&amp;M) expenses, G&amp;A expenses and Product Development (R&amp;D) expenses. The following table summarizes OE in 4Q and year 2023 compared to the same periods in 2022 by OE category:</P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:59.4pt><P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>OE<BR><FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=bottom style=width:54pt><P align=center style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>4Q 2023</FONT></P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>4Q 2022</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>2023</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>2022</FONT></P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt stHtmlOvrFontNm;margin:0'>S&amp;M:</P>
</TD><TD valign=top style=width:54pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>$ 475</P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'> &nbsp;3.9</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>$ 441</P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'> &nbsp;3.3</P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>$ &nbsp;&nbsp;1,685</P>
</TD><TD valign=top style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'> &nbsp;3.4</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>$ &nbsp; 1,507</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'> &nbsp;2.9</P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt stHtmlOvrFontNm;margin:0'>G&amp;A:</P>
</TD><TD valign=top style=width:54pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>2,533 </P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>20.5</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>2,693</P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>19.8</P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'> &nbsp;&nbsp;11,016</P>
</TD><TD valign=top style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>21.9</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'> &nbsp;&nbsp;&nbsp;10,407</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>19.9</P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>R&amp;D:</FONT></P>
</TD><TD valign=top style=width:54pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;146</FONT></P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;1.2</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;123</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;0.9</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;560</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;1.1</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 493</FONT></P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;0.9</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt stHtmlOvrFontNm;margin:0'>Total OE:</P>
</TD><TD valign=top style=width:54pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>3,154</P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>25.6</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>3,257</P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>24.0</P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'> &nbsp;&nbsp;13,261</P>
</TD><TD valign=top style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>26.4</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'> &nbsp; 12,407</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>23.7</P>
</TD></TR>
</TABLE>
<P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>The following table summarizes &#8220;constant currency&#8221; OE in 4Q and year 2023 compared to the same periods in 2022 by OE category:</P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:59.4pt><P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>OE<BR><FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=bottom style=width:54pt><P align=center style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>4Q 2023<BR><FONT style='border-bottom:1px solid #000000'>const FX</FONT></P>
</TD><TD valign=bottom style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
</TD><TD valign=bottom style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>4Q 2022</FONT></P>
</TD><TD valign=bottom style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
</TD><TD valign=bottom style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>2023<BR><FONT style='border-bottom:1px solid #000000'>const FX</FONT></P>
</TD><TD valign=bottom style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
</TD><TD valign=bottom style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>2022</FONT></P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt stHtmlOvrFontNm;margin:0'>S&amp;M:</P>
</TD><TD valign=top style=width:54pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>$ 471</P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:52.4pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>$ 441</P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>$ &nbsp;&nbsp;&nbsp;1,685</P>
</TD><TD valign=top style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>$  &nbsp;&nbsp;1,507</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt stHtmlOvrFontNm;margin:0'>G&amp;A:</P>
</TD><TD valign=top style=width:54pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>2,492</P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:52.4pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>2,693</P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'> &nbsp;&nbsp;&nbsp;10,986</P>
</TD><TD valign=top style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'> &nbsp;&nbsp; 10,407</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>R&amp;D:</FONT></P>
</TD><TD valign=top style=width:54pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;146</FONT></P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:52.4pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;123</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;560</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp; &nbsp; &nbsp; &nbsp;493</FONT></P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt stHtmlOvrFontNm;margin:0'>Total OE:</P>
</TD><TD valign=top style=width:54pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>3,109</P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:52.4pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>3,257</P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'> &nbsp;&nbsp;&nbsp;12,231</P>
</TD><TD valign=top style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'> &nbsp; 12,407</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>The FX rate change impact in both periods was minor. &nbsp;A stronger EUR and GBP, partially offset by a weaker AUD and CAD, increased total 4Q 2023 OE by $45 and year 2023 OE by $30 compared to constant currency. &nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>S&amp;M and R&amp;D expenses increased in 2023 primarily as a result of cost-of-living salary increases. &nbsp;Constant currency S&amp;M expenses were $4 lower in the 4Q, and about the same for the year. Since almost all product development is carried out in the U.S., there was no material R&amp;D expense impact as a result of FX rate changes.</P>
<P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>With the exception of salary increases in all departments, the primary changes in OE were in the G&amp;A expense category. The two major G&amp;A expense changes were in litigation expense and in the amortization of the $21 million identifiable intangible asset (IIA) associated with UTMD&#8217;s 2019 purchase of CooperSurgical Inc&#8217;s (CSI&#8217;s) exclusive right to distribute the Filshie Clip System in the U.S. The CSI IIA amortization expense, which had been $1,105 per quarter since February 2019, ended during 4Q 2023. Litigation expenses were $401 higher in 4Q 2023, and $990 higher for the 2023 year, compared to the same periods in 2022. &nbsp;Without litigation expense and IIA amortization associated with the Filshie Clip System, consolidated USD G&amp;A OE were $149 higher in 4Q 2023, and $344 higher in year 2023, compared to the same periods in 2022. On a constant currency basis, without litigation expense and IIA amortization associated with the Filshie Clip System, consolidated USD G&amp;A OE were $134 higher in 4Q 2023, and $338 higher in year 2023, compared to the same periods in 2022. &nbsp;For the year, litigation expenses were $1,660 in 2023 compared to $670 in 2022. &nbsp;Litigation expenses in both years were the result of U.S. product liability litigation which remains in discovery. UTMD must defend its longstanding reputation for providing very safe and effective devices.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt stHtmlOvrFontNm;margin:0'>A division of G&amp;A expenses by location follows: </P>
<TABLE style=border-collapse:collapse;width:436.5pt><TR><TD valign=bottom style=width:89.95pt><P style='font:11pt stHtmlOvrFontNm;margin:0'>G&amp;A Exp<BR><FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=bottom style=width:49.15pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>4Q 2023</FONT></P>
</TD><TD valign=bottom style='width:35.9pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:52pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>4Q 2022</FONT></P>
</TD><TD valign=bottom style='width:33.1pt;border-right:1.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:52.1pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>2023</FONT></P>
</TD><TD valign=bottom style='width:37.45pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:51.75pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>2022</FONT></P>
</TD><TD valign=bottom style=width:35.1pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:89.95pt><P style='font:11pt stHtmlOvrFontNm;margin:0'>IIA Amort - UK:</P>
</TD><TD valign=bottom style=width:49.15pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>$ &nbsp;493</P>
</TD><TD valign=bottom style='width:35.9pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'> 4.0</P>
</TD><TD valign=bottom style='width:52pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>$ &nbsp;467</P>
</TD><TD valign=bottom style='width:33.1pt;border-right:1.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'> &nbsp;3.4</P>
</TD><TD valign=bottom style='width:52.1pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>$ 1,977</P>
</TD><TD valign=bottom style='width:37.45pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'> &nbsp;3.9</P>
</TD><TD valign=bottom style='width:51.75pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>$1,965</P>
</TD><TD valign=bottom style=width:35.1pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'> &nbsp;3.8</P>
</TD></TR>
<TR><TD valign=top style=width:89.95pt><P style='font:11pt stHtmlOvrFontNm;margin:0'>IIA Amort&#8211; CSI:</P>
</TD><TD valign=bottom style=width:49.15pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>368</P>
</TD><TD valign=bottom style='width:35.9pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>3.0</P>
</TD><TD valign=bottom style='width:52pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>1,105</P>
</TD><TD valign=bottom style='width:33.1pt;border-right:1.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>8.1</P>
</TD><TD valign=bottom style='width:52.1pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>3,684</P>
</TD><TD valign=bottom style='width:37.45pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>7.3</P>
</TD><TD valign=bottom style='width:51.75pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>4,421</P>
</TD><TD valign=bottom style=width:35.1pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>8.5</P>
</TD></TR>
<TR><TD valign=top style=width:89.95pt><P style='font:11pt stHtmlOvrFontNm;margin:0'>UK:</P>
</TD><TD valign=bottom style=width:49.15pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>179</P>
</TD><TD valign=bottom style='width:35.9pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:52pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>145</P>
</TD><TD valign=bottom style='width:33.1pt;border-right:1.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:52.1pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>678</P>
</TD><TD valign=bottom style='width:37.45pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:51.75pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>573</P>
</TD><TD valign=bottom style=width:35.1pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:89.95pt><P style='font:11pt stHtmlOvrFontNm;margin:0'>US:</P>
</TD><TD valign=bottom style=width:49.15pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>1,339</P>
</TD><TD valign=bottom style='width:35.9pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:52pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>809</P>
</TD><TD valign=bottom style='width:33.1pt;border-right:1.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:52.1pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>4,091</P>
</TD><TD valign=bottom style='width:37.45pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:51.75pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>2,826</P>
</TD><TD valign=bottom style=width:35.1pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:89.95pt><P style='font:11pt stHtmlOvrFontNm;margin:0'>IRE:</P>
</TD><TD valign=bottom style=width:49.15pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>95</P>
</TD><TD valign=bottom style='width:35.9pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:52pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>94</P>
</TD><TD valign=bottom style='width:33.1pt;border-right:1.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:52.1pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>322</P>
</TD><TD valign=bottom style='width:37.45pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:51.75pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>319</P>
</TD><TD valign=bottom style=width:35.1pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:89.95pt><P style='font:11pt stHtmlOvrFontNm;margin:0'>AUS:</P>
</TD><TD valign=bottom style=width:49.15pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>28</P>
</TD><TD valign=bottom style='width:35.9pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:52pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>42</P>
</TD><TD valign=bottom style='width:33.1pt;border-right:1.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:52.1pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>134</P>
</TD><TD valign=bottom style='width:37.45pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:51.75pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>166</P>
</TD><TD valign=bottom style=width:35.1pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style='width:89.95pt;border-bottom:0.5pt solid #000000'><P style='font:11pt stHtmlOvrFontNm;margin:0'>CAN:</P>
</TD><TD valign=bottom style='width:49.15pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>31</P>
</TD><TD valign=bottom style='width:35.9pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:52pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>31</P>
</TD><TD valign=bottom style='width:33.1pt;border-bottom:0.5pt solid #000000;border-right:1.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:52.1pt;border-left:1.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>130</P>
</TD><TD valign=bottom style='width:37.45pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:51.75pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>137</P>
</TD><TD valign=bottom style='width:35.1pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style='width:89.95pt;border-top:0.5pt solid #000000'><P style='font:11pt stHtmlOvrFontNm;margin:0'>Total G&amp;A</P>
</TD><TD valign=bottom style='width:49.15pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>2,533</P>
</TD><TD valign=bottom style='width:35.9pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>20.5</P>
</TD><TD valign=bottom style='width:52pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>2,693</P>
</TD><TD valign=bottom style='width:33.1pt;border-top:0.5pt solid #000000;border-right:1.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>19.8</P>
</TD><TD valign=bottom style='width:52.1pt;border-top:0.5pt solid #000000;border-left:1.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>11,016</P>
</TD><TD valign=bottom style='width:37.45pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>21.9</P>
</TD><TD valign=bottom style='width:51.75pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>10,407</P>
</TD><TD valign=bottom style='width:35.1pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>19.9</P>
</TD></TR>
</TABLE>
<P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>In both periods, the USD was weaker relative to the EUR and GBP, but stronger relative to the AUD and CAD. &nbsp;The GBP-denominated IIA Amort - UK was the same in both years&#8217; periods. Looking forward, the IIA- CSI will be zero. &nbsp; </P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>Income Before Tax (EBT)</FONT> </P>
<P style='font:11pt stHtmlOvrFontNm;margin-top:0pt;margin-bottom:6pt'>EBT results from subtracting net non-operating expense (NOE) or adding net non-operating income (NOI) from or to, as applicable, OI. Consolidated 2023 EBT was $20,089 (40.0% of sales) compared to $20,659 (39.5% of sales) in 2022. Consolidated 4Q 2023 EBT was $5,017 (40.7% of sales) compared to $5,591 (41.2% of sales) in 4Q 2022. &nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin-top:0pt;margin-bottom:6pt'>NOE/NOI includes the combination of 1) expenses from loan interest and bank fees; 2) expenses or income from losses or gains from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms; and 3) income from rent of underutilized property, investment income and royalties received from licensing the Company&#8217;s technology. Negative NOE is NOI. Net NOI in 2023 was $3,312 compared to $869 NOI in 2022. Net NOI in 4Q 2023 was $1,073 compared to $521 NOI in 4Q 2022. The increase in 4Q 2023 and year 2023 NOI was due primarily to higher interest rates for higher cash balances. </P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>EBITDA is a non-US GAAP metric that measures profitability performance without factoring in effects of financing, accounting decisions regarding non-cash expenses, capital expenditures or tax environments. Consolidated EBT excluding the remeasured bank balance currency gain or loss, interest expense, noncash effects of depreciation, amortization of intangible assets and stock option expense (&#8220;adjusted consolidated EBITDA&#8221;) were $26,635 for the year 2023 compared to $27,891 in 2022, a decrease of 4.5% in this annual operating metric. <A name=_Hlk156468792 />Adjusted consolidated EBITDA in 4Q 2023 was $6,115 compared to $7,404 in 4Q 2022. </P>
<P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>UTMD&#8217;s adjusted consolidated EBITDA as a percentage of sales was 53.0% for the year 2023 compared to 53.3% in 2022. UTMD&#8217;s adjusted consolidated EBITDA as a percentage of sales was 49.6% in 4Q 2023 compared to 54.5% in 4Q 2022. </P>
<P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>Management believes that this operating performance metric provides meaningful supplemental information to both management and investors and confirms UTMD&#8217;s ongoing excellent financial performance. </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>UTMD&#8217;s non-US GAAP adjusted consolidated EBITDA is the sum of the elements in the following table, each element of which is a US GAAP number:</P>
<TABLE style=border-collapse:collapse;width:549pt;margin-left:5.4pt><TR><TD valign=top style=width:207pt><P style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>4Q 2023</FONT></P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>4Q 2022</FONT></P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'> 2023</FONT></P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'> 2022</FONT></P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:207pt><P style='font:11pt stHtmlOvrFontNm;margin:0'>EBT</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>$5,017</P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>$5,591</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>$20,089</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>$20,659</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:207pt><P style='font:11pt stHtmlOvrFontNm;margin:0'>Depreciation Expense</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>158</P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>158</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>624</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>612</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:207pt><P style='font:11pt stHtmlOvrFontNm;margin:0'>Femcare IIA Amortization Expense</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>493</P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>467</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>1,977</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>1,965</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:207pt><P style='font:11pt stHtmlOvrFontNm;margin:0'>CSI IIA Amortization Expense</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>368</P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>1,105</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>3,684</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>4,421</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:207pt><P style='font:11pt stHtmlOvrFontNm;margin:0'>Other Non-Cash Amortization Expense</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'> 7</P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>8</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>31</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>31</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:207pt><P style='font:11pt stHtmlOvrFontNm;margin:0'>Stock Option Compensation Expense</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>73</P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>62</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>225 </P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>183</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:207pt><P style='font:11pt stHtmlOvrFontNm;margin:0'>Interest Expense</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>-</P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>-</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>-</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>-</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style='width:207pt;border-bottom:0.5pt solid #000000'><P style='font:11pt stHtmlOvrFontNm;margin:0'>Remeasured Foreign Currency Balances</P>
</TD><TD valign=top style='width:49.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>(1)</P>
</TD><TD valign=top style='width:58.5pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>13</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>5</P>
</TD><TD valign=top style='width:58.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>20</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style='width:207pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>UTMD non-US GAAP EBITDA:</P>
</TD><TD valign=top style='width:49.5pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>$6,115</P>
</TD><TD valign=top style='width:58.5pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>$7,404</P>
</TD><TD valign=top style='width:58.5pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>$26,635</P>
</TD><TD valign=top style='width:58.5pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>$27,891</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>Net Income (NI)</FONT> </P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>NI for the year 2023 of $16,635 (33.1% of sales) was 1.0% higher than NI of $16,473 (31.5% of sales) in 2022. NI in 4Q 2023 of $4,287 (34.8% of sales) was 5.9% lower than NI of $4,555 (33.6% of sales) in 4Q 2022. The average consolidated income tax provisions (as a % of the same period EBT) in 2023 and 2022 were 17.2% and 20.3% respectively, and were 14.6% and 18.5% in 4Q 2023 and 4Q 2022 respectively. The lower overall rates in 2023 were due to a portion of NOI being tax exempt in the U.S. Otherwise, the overall consolidated income tax provision rate varies as the mix in taxable income among U.S. and foreign subsidiaries with differing income tax rates differs from period to period. UTMD has consistently paid millions of dollars in income taxes annually. Other than the UK increasing its corporate income tax rate from 19% to 25% effective on April 1, 2023, the basic 2023 corporate income tax rates in each of the sovereignties were the same as in the prior year. </P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>Earnings per share (EPS)</FONT>. </P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>Despite 15.2% lower Operating Income for the 2023 year, diluted 2023 EPS of $4.574 compared to $4.522 in 2022 were higher by 1.2%. &nbsp;Diluted EPS in 4Q 2023 were $1.180 compared to $1.253 in 4Q 2022. The increase in EPS for the year was a result of improvement in NOI from higher interest on higher cash balances and a lower income tax rate provision. Diluted shares were 3,637,071 for the 2023 year compared to 3,643,256 in 2022. Diluted shares were 3,632,064 in 4Q 2023 compared to 3,634,686 in 4Q 2022. </P>
<P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>The number of shares used for calculating 4Q 2023 and year 2023 EPS were higher than the December 31, 2023 outstanding shares balance of 3,629,525 because of a time-weighted calculation of average outstanding shares plus dilution from unexercised employee options. Outstanding shares at the end of calendar year 2023 of 3,629,525 compared to 3,627,767 at the end of 2022. The difference was due to 1,758 shares in employee option exercises during 2023. The total number of outstanding unexercised employee and outside director options at December 31, 2023 was 84,301 at an average exercise price of $74.56, including shares awarded but not yet vested. This compares to 67,433 unexercised option shares at the end of 2022 at an average exercise price of $73.66/ share, including shares awarded but not vested. </P>
<P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>The number of shares added as a dilution factor for the year 2023 was 8,303 compared to 5,934 in 2022. The number of shares added as a dilution factor for 4Q 2023 was 2,539 compared to 7,630 in 4Q 2022. In October 2023, 19,000 non-qualified option shares were awarded to 48 employees at an exercise price of $77.07 per share. In October 2022, 20,600 ISO option shares were awarded to 40 employees at an exercise price of $82.60 per share. UTMD&#8217;s stock option plans continue to be an integral part of attracting and retaining productive employees. Over time, option plans have not been dilutive to stockholders, as the Company has consistently repurchased substantially more shares in the open market at lower prices than it has awarded in options.</P>
<P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>UTMD paid <A name=_Hlk156298844 />$1,071 ($0.295/share) in dividends to stockholders in 4Q 2023 compared to $1,051 ($0.290/share) paid in 4Q 2022. UTMD paid $4,282 ($1.18/share) in dividends to stockholders in 2023 compared to $3,162 ($0.87/ share) in dividends in 2022. The dividends paid in 2022 represented only </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'><FONT style=font-size:11pt>three calendar quarters because of an early dividend payment in 4Q 2021. Also, in 2022 UTMD made $2,495 in share repurchases. As declared in October 2023, UTMD&#8217;s regular quarterly dividend was increased to $0.300 per share starting with a January 2024 payment. &nbsp;</FONT></P>
<P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>In 2Q 2022, UTMD repurchased 30,105 of its shares in the open market at $82.88/ share. No shares were repurchased in 2023. The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders. UTMD&#8217;s closing share price at the end of 2023 was $84.22, down 16.2% from the closing price of $100.53 at the end of 2022, and down 2.1% from the end of the prior calendar quarter. In comparison, the major stock market indices were all substantially higher for the year 2023: the Dow Jones Industrial Average was up 13.7%, the S&amp;P 500 Index up 24.2% and the NASDAQ Composite, in which UTMD shares are traded, up 43.4%. &nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>Balance Sheet</FONT></P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>Please see the audited December 31, 2023 Balance Sheet at the end of this report. At the end of 2023 compared to the end of 2022, UTMD&#8217;s cash and investments increased $17.8 million to $92.9 million as a result of $26.6 million operating EBITDA minus $4.8 million paid in income taxes, $4.3 million in cash dividends paid to stockholders, and a $0.1 million decrease in non-cash working capital. The lower non-cash working capital was in spite of a $0.8 million increase in inventories as a hedge against supply chain disruptions and inflationary costs. At December 31, 2023, Net Intangible Assets decreased to 13.8% of total consolidated assets from 19.2% on December 31, 2022. &nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>Financial ratios as of December 31, 2023 which may be of interest to stockholders follow:</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:-18pt'>1)</KBD>Current Ratio = 22.9&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:-18pt'>2)</KBD>Days in Trade Receivables (based on 4Q 2023 sales activity) = 24.3&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:-18pt'>3)</KBD>Average Inventory Turns in 2023 (based on 2023 CGS) = 2.2&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt stHtmlOvrFontNm;margin-left:-18pt'>4)</KBD>2023 ROE (before dividends) = 14%&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>Investors are cautioned that this press release contains forward looking statements and that actual events may differ from those projected. &nbsp;Risk factors that could cause results to differ materially from those projected include global economic conditions, market acceptance of products, regulatory approvals of products, regulatory intervention in current operations, government intervention in healthcare in general, tax reforms, the Company&#8217;s ability to efficiently manufacture, market and sell products, cybersecurity and foreign currency exchange rates, among other factors that have been and will be outlined in UTMD&#8217;s public disclosure filings with the SEC. &nbsp;UTMD&#8217;s 2023 SEC Form 10-K will be filed on or before March 29, 2024, and can be accessed on <FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><I>www.utahmed.com</I></FONT>.</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
<P style='font:11pt stHtmlOvrFontNm;margin:0'>Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over one hundred countries around the world as the standard for obtaining optimal long term outcomes for their patients. &nbsp;For more information about Utah Medical Products, Inc., visit UTMD&#8217;s website at<B><I> </I></B><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><I>www.utahmed.com</I></FONT>.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt stHtmlOvrFontNm;margin:0'><FONT style=font-size:13pt><B>Utah Medical Products, Inc.</B></FONT></P>
<P style='font:10pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
<P style='font:10pt stHtmlOvrFontNm;margin-top:6pt;margin-bottom:0pt'>INCOME STATEMENT, Fourth Quarter (three months ended December 31)</P>
<P style='font:10pt stHtmlOvrFontNm;margin:0'>(in thousands except earnings per share):</P>
<TABLE style=border-collapse:collapse;width:517.2pt><TR><TD valign=top style=width:149.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>4Q 2023</FONT></P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>4Q 2022</FONT></P>
</TD><TD valign=top style=width:86.25pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>Percent Change</FONT></P>
</TD><TD valign=top style=width:65.55pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:149.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>Net Sales</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>$  12,333</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>$ &nbsp;13,575</P>
</TD><TD valign=bottom style=width:86.25pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0;margin-right:9pt'> &nbsp;(9.1%)</P>
</TD><TD valign=top style=width:65.55pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:149.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>Gross Profit</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>7,098</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>8,327</P>
</TD><TD valign=bottom style=width:86.25pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0;margin-right:9pt'> (14.8%)</P>
</TD><TD valign=top style=width:65.55pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:149.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>Operating Income</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>3,944</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>5,070</P>
</TD><TD valign=bottom style=width:86.25pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0;margin-right:9pt'> (22.2%)</P>
</TD><TD valign=top style=width:65.55pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:149.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>Income Before Tax</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>5,017</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>5,591</P>
</TD><TD valign=bottom style=width:86.25pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0;margin-right:9pt'> (10.3%)</P>
</TD><TD valign=top style=width:65.55pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:149.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>Net Income</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>4,287</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>4,555</P>
</TD><TD valign=bottom style=width:86.25pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0;margin-right:9pt'> &nbsp;(5.9%)</P>
</TD><TD valign=top style=width:65.55pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:149.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>Diluted EPS</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>$ &nbsp;1.180</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>$ &nbsp;1.253</P>
</TD><TD valign=bottom style=width:86.25pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0;margin-right:9pt'> &nbsp;(5.8%)</P>
</TD><TD valign=top style=width:65.55pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:149.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>Shares Outstanding (diluted)</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>3,632</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>3,635</P>
</TD><TD valign=bottom style=width:86.25pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0;margin-right:9pt'>&nbsp;</P>
</TD><TD valign=top style=width:65.55pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
<P style='font:10pt stHtmlOvrFontNm;margin:0'>INCOME STATEMENT, Twelve Months (Calendar Year ended December 31)</P>
<P style='font:10pt stHtmlOvrFontNm;margin:0'>(in thousands except earnings per share): </P>
<TABLE style=border-collapse:collapse;width:519.75pt><TR><TD valign=top style=width:144.9pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:73.35pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>2023</FONT></P>
</TD><TD valign=top style=width:72pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>2022</FONT></P>
</TD><TD valign=top style=width:87.75pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>Percent Change</FONT></P>
</TD><TD valign=top style=width:65.25pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.5pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:144.9pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>Net Sales</P>
</TD><TD valign=top style=width:73.35pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>$  50,224</P>
</TD><TD valign=top style=width:72pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>$  52,281</P>
</TD><TD valign=bottom style=width:87.75pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0;margin-right:6pt'>(3.9%)</P>
</TD><TD valign=top style=width:65.25pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:144.9pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>Gross Profit</P>
</TD><TD valign=top style=width:73.35pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>30,038</P>
</TD><TD valign=top style=width:72pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>32,196</P>
</TD><TD valign=bottom style=width:87.75pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0;margin-right:6pt'>(6.7%)</P>
</TD><TD valign=top style=width:65.25pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:144.9pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>Operating Income</P>
</TD><TD valign=top style=width:73.35pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>16,777</P>
</TD><TD valign=top style=width:72pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>19,790</P>
</TD><TD valign=bottom style=width:87.75pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0;margin-right:6pt'>(15.2%)</P>
</TD><TD valign=top style=width:65.25pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:144.9pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>Income Before Tax</P>
</TD><TD valign=top style=width:73.35pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>20,089</P>
</TD><TD valign=top style=width:72pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>20,659</P>
</TD><TD valign=bottom style=width:87.75pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0;margin-right:6pt'>(2.8%)</P>
</TD><TD valign=top style=width:65.25pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:144.9pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>Net Income</P>
</TD><TD valign=top style=width:73.35pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>16,635</P>
</TD><TD valign=top style=width:72pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>16,473</P>
</TD><TD valign=bottom style=width:87.75pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0;margin-right:6pt'>1.0%</P>
</TD><TD valign=top style=width:65.25pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:144.9pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>Diluted EPS</P>
</TD><TD valign=top style=width:73.35pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>$  4.574</P>
</TD><TD valign=top style=width:72pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>$  4.522</P>
</TD><TD valign=bottom style=width:87.75pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0;margin-right:6pt'>1.2%</P>
</TD><TD valign=top style=width:65.25pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:144.9pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>Shares Outstanding (diluted)</P>
</TD><TD valign=top style=width:73.35pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>3,637</P>
</TD><TD valign=top style=width:72pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>3,643</P>
</TD><TD valign=bottom style=width:87.75pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0;margin-right:6pt'>&nbsp;</P>
</TD><TD valign=top style=width:65.25pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
<P style='font:10pt stHtmlOvrFontNm;margin:0'><KBD style='position:absolute;font:10pt stHtmlOvrFontNm;margin-left:0pt'>BALANCE SHEET</KBD><KBD style=margin-left:252pt></KBD> &nbsp;</P>
<TABLE style=border-collapse:collapse><TR style=height:21.6pt><TD valign=top style=width:185.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>(in thousands)</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>(audited)</P>
<P align=right style='font:10pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>DEC 31, 2023</FONT></P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(unaudited)</P>
<P align=right style='font:10pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>SEP 30, 2023</FONT></P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>(audited)</P>
<P align=right style='font:10pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>DEC 31, 2022</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>Assets</FONT></P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR style=height:9.9pt><TD valign=top style=width:185.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'> &nbsp;&nbsp;Cash &amp; Investments</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>$ &nbsp;92,869</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>$ &nbsp;88,209</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>$ &nbsp;75,052</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'> &nbsp;&nbsp;Accounts &amp; Other Receivables, Net</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>3,390</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>3,487</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>5,538</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'> &nbsp;&nbsp;Inventories</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>9,582</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>9,709</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>8,814</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'> &nbsp;&nbsp;Other Current Assets</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>428</FONT></P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>442</FONT></P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>515</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;Total Current Assets</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>106,269</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>101,847</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>89,919</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>Property &amp; Equipment, Net</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>10,552</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>10,347</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>10,224</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>Intangible Assets, Net</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>18,637</FONT></P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>19,049</FONT></P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>23,731</FONT></P>
</TD></TR>
<TR style=height:21.15pt><TD valign=top style=width:185.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Assets</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>$ &nbsp;135,458</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>$ &nbsp;131,243</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>$ &nbsp;123,874</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>Liabilities &amp; Stockholders&#8217; Equity</FONT></P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>Accounts Payable</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>$ &nbsp;769</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>$ &nbsp;511</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>$ &nbsp;1,218</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>REPAT Tax Payable</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>611</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>419</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>419</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>Other Accrued Liabilities</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>3,263</FONT></P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>3,247</FONT></P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>4,323</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'> &nbsp;&nbsp;Total Current Liabilities</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'> &nbsp;$ &nbsp;4,643</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'> &nbsp;$ &nbsp;4,177</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'> &nbsp;$ &nbsp;5,960</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>Deferred Tax Liability &#8211;&nbsp;Intangible Assets</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>1,120</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>1,196</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>1,513</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>Long Term Lease Liability </P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>295</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>305</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>341</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>Long Term REPAT Tax Payable</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>765</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>1,256</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>1,256</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>Deferred Revenue and Income Taxes</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>322</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>607</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>549</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'>Stockholders&#8217; Equity</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>128,313</FONT></P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>123,702</FONT></P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'><FONT style='border-bottom:1px solid #000000'>114,255</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt stHtmlOvrFontNm;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities &amp; Stockholders&#8217; Equity</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>$ &nbsp;135,458</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>$ &nbsp;131,243</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt stHtmlOvrFontNm;margin:0'>$ &nbsp;123,874</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>utmd-20240130_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK5GW761L0VDHRHPYZ]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20240130"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20240130.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>utmd-20240130_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK5GW761L0VDHRHPYZ]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20240130"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressAddressLine1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Address Line One</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressAddressLine1' xlink:to='lab_dei_EntityAddressAddressLine1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityShellCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Shell Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityShellCompany' xlink:to='lab_dei_EntityShellCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TextBlockAbstract' xlink:to='lab_us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityTaxIdentificationNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tax Identification Number (TIN)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityTaxIdentificationNumber' xlink:to='lab_dei_EntityTaxIdentificationNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Period End date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementIssuerTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Issuer Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementIssuerTenderOffer' xlink:to='lab_dei_PreCommencementIssuerTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CityAreaCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>City Area Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CityAreaCode' xlink:to='lab_dei_CityAreaCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressPostalZipCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Postal Zip Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressPostalZipCode' xlink:to='lab_dei_EntityAddressPostalZipCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current with reporting</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SecurityExchangeName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Exchange</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SecurityExchangeName' xlink:to='lab_dei_SecurityExchangeName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_WrittenCommunications' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Written Communications</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_WrittenCommunications' xlink:to='lab_dei_WrittenCommunications'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressStateOrProvince' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, State or Province</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressStateOrProvince' xlink:to='lab_dei_EntityAddressStateOrProvince'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntitySmallBusiness' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Small Business</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntitySmallBusiness' xlink:to='lab_dei_EntitySmallBusiness'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityIncorporationStateCountryCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Incorporation, State or Country Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityIncorporationStateCountryCode' xlink:to='lab_dei_EntityIncorporationStateCountryCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentDescription' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Description</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentDescription' xlink:to='lab_dei_AmendmentDescription'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityInteractiveDataCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interactive Data Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityInteractiveDataCurrent' xlink:to='lab_dei_EntityInteractiveDataCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Fiscal Year End</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityEmergingGrowthCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Emerging Growth Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityEmergingGrowthCompany' xlink:to='lab_dei_EntityEmergingGrowthCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant CIK</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_TradingSymbol' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Symbol</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_TradingSymbol' xlink:to='lab_dei_TradingSymbol'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Number of common stock shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_LocalPhoneNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Local Phone Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_LocalPhoneNumber' xlink:to='lab_dei_LocalPhoneNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityExTransitionPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Ex Transition Period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityExTransitionPeriod' xlink:to='lab_dei_EntityExTransitionPeriod'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SolicitingMaterial' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Soliciting Material</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SolicitingMaterial' xlink:to='lab_dei_SolicitingMaterial'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>SEC Form</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementTenderOffer' xlink:to='lab_dei_PreCommencementTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressCityOrTown' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, City or Town</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressCityOrTown' xlink:to='lab_dei_EntityAddressCityOrTown'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFileNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity File Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFileNumber' xlink:to='lab_dei_EntityFileNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Voluntary filer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>utmd-20240130_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK5GW761L0VDHRHPYZ]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20240130"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20240130.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentType' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_TradingSymbol' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SecurityExchangeName' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityTaxIdentificationNumber' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityInteractiveDataCurrent' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityShellCompany' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntitySmallBusiness' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityEmergingGrowthCompany' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityExTransitionPeriod' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentDescription' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityIncorporationStateCountryCode' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFileNumber' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressAddressLine1' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressCityOrTown' use='optional' order='24.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressStateOrProvince' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressPostalZipCode' use='optional' order='26.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CityAreaCode' use='optional' order='27.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_LocalPhoneNumber' use='optional' order='28.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_WrittenCommunications' use='optional' order='29.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SolicitingMaterial' use='optional' order='30.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementTenderOffer' use='optional' order='31.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementIssuerTenderOffer' use='optional' order='32.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='33.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>utmd-20240130.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK5GW761L0VDHRHPYZ]. www.edgarsuite.com -->
<schema xmlns='http://www.w3.org/2001/XMLSchema' xmlns:us-gaap='http://fasb.org/us-gaap/2023' xmlns:fil='http://utahmed.com/20240130' xmlns:dei='http://xbrl.sec.gov/dei/2023' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' targetNamespace='http://utahmed.com/20240130' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xbrli='http://www.xbrl.org/2003/instance' elementFormDefault='qualified' attributeFormDefault='unqualified'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20240130_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20240130_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20240130_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import schemaLocation='https://www.xbrl.org/dtr/type/2022-03-31/types.xsd' namespace='http://www.xbrl.org/dtr/type/2022-03-31'/>
	<import namespace='http://xbrl.sec.gov/dei/2023' schemaLocation='https://xbrl.sec.gov/dei/2023/dei-2023.xsd'/>
	<import namespace='http://fasb.org/us-gaap/2023' schemaLocation='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd'/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139740500547088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Registrant CIK</a></td>
<td class="text">0000706698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">UTAH MEDICAL PRODUCTS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">SEC Form</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Period End date</a></td>
<td class="text">Jan. 30,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Tax Identification Number (TIN)</a></td>
<td class="text">87-0342734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-12575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7043 South 300 West<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Midvale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">566-1200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( +MV/E@'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "[=CY8Z\Z_P^\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9)1
M2\,P$,>_BN2]O;1U@J'+BV-/"H(#Q;>0W+9@DX;DI-VW-ZU;A^@'\#%W__SN
M=W"M#D+W$9]C'S"2Q70SNLXGH<.:'8F" $CZB$ZE,B=\;N[[Z!3E9SQ 4/I#
M'1!JSN_ (2FC2,$$+,)"9+(U6NB(BOIXQAN]X,-G[&:8T8 =.O24H"HK8'*:
M&$YCU\(5,,$(HTO?!30+<:[^B9T[P,[),=DE-0Q#.31S+N]0P=O3X\N\;F%]
M(N4UYE_)"CH%7+/+Y-?F8;/;,EGS^K;@5='P774O5HU8\??)]8??5=CUQN[M
M/S:^",H6?MV%_ )02P,$%     @ NW8^6)E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MTG1X#SY['R73>RHY_U=3_ 102P,$%     @ NW8^6)>*NQS     $P(   L
M  !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%
MG;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XU
MA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.
M\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,B
MM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " "[=CY8'#AEZC\!
M   \ @  #P   'AL+W=O<FMB;V]K+GAM;(U1RV["0 S\E=5^0!-0BU1$N)0^
MD*H6E8K[DG6(Q3XBKP,M7U\G452D7GKR>FR-9V87YTC'?8Q']>5=2(6NF9MY
MEJ6R!F_236P@R*2*Y U+2X<L-03&IAJ O<NF>3[+O,&@EXN1:T/9=1,92L88
M!.R '<(Y_<Z[5ITPX1X=\G>A^[<#K3P&]'@!6^A<JU3'\TLDO,3 QFU+BLX5
M>C(,=D",Y1]XVXG\-/O4(VSV'T:$%'J6"V&%E+C?Z/F-:#R!+ ]=R_$)'0.M
M#,,SQ;;!<.AHQ$5V9://8:Q#B'/Z3XRQJK"$52Q;#X&'' E<)S"D&IND53 >
M"CVN*!.L>@PL(:EU&*ADMW,JI]=V<,TB]RI#FJ,,:&T'X:-:"Q4&L&]R( DN
MR94;4EWI>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%     @ NW8^6"0>
MFZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#
M, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W
M;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9
MHIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJ
MEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( +MV
M/EAED'F2&0$  ,\#   3    6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%
MKQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/
M$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4
MZ]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N
M6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC
M JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@A
MLO7L^T%.6X.^D<WC_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_
M7G\!4$L! A0#%     @ NW8^6 =!36*!    L0   !               ( !
M     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "[=CY8Z\Z_P^\    K
M @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M    " "[=CY8F5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE
M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( +MV/EC8%Q6-X@,  )<.   8
M          " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " "[=CY8GZ ;\+$"  #B#   #0              @ $F#   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( +MV/EB7BKL<P    !,"   +
M  "  0(/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( +MV/E@<.&7J/P$  #P"
M   /              "  >L/  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" "[=CY8)!Z;HJT   #X 0  &@              @ %7$0  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "[=CY899!YDAD!  #/ P
M$P              @ $\$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
.."0 ) #X"  "&$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>19</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="utmd-20240130.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="utmd-20240130.htm">utmd-20240130.htm</File>
    <File>utmd-20240130.xsd</File>
    <File>utmd-20240130_def.xml</File>
    <File>utmd-20240130_lab.xml</File>
    <File>utmd-20240130_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="19">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "utmd-20240130.htm": {
   "nsprefix": "fil",
   "nsuri": "http://utahmed.com/20240130",
   "dts": {
    "inline": {
     "local": [
      "utmd-20240130.htm"
     ]
    },
    "schema": {
     "local": [
      "utmd-20240130.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "utmd-20240130_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "utmd-20240130_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "utmd-20240130_pre.xml"
     ]
    }
   },
   "keyStandard": 19,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 34,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 19
   },
   "report": {
    "R1": {
     "role": "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation",
     "longName": "000010 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "D240130",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240130.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D240130",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240130.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fiscal Year End",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period End date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Form",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registrant CIK",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of common stock shares outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current with reporting",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Identification Number (TIN)",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Voluntary filer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Exchange",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Details"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://utahmed.com/20240130/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001096906-24-000127-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001096906-24-000127-xbrl.zip
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M,)=TQJ1Q\J[6DA%7C,B@JX94L -2<V^PFTOJP2",%!.DZ?O!C::'/( ;QSR
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MW__,U#?8ZI.,E$X^R:\_ZE_]/U!+ P04    " "[=CY8>JP 5=@"   ^"0
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M(LKMHU!^7W!RQ373\UO3RS)U[50!C+0K1Z.=J$+5Z@X[@?F$ 8"@3%Y?8D[
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M"LC\-,MJK!L\XT*9-5XS2R0\K]CEM2 /6052X*R:[#.%3=3D#NN+5I2'":8
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M@@TCNB;]>;J3-Y@_YI])3G?^!5!+ P04    " "[=CY8AH5S'%TS  #+FP$
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M-+Z+XB$23''M%3%XG$:CEVW81?%G-TK3:/A28X#]<GHNQQE%B8_D]]+K)E$
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M(F)(ZR-:=$4V'K, RXR08B9@,B^/1*W+?<MT_=D2H,QBNN+HL(D_=Q@*A50
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MW*7]KGY<"5;"&&G4I=F<!'MV:O[H8G,US] >^B7W3.!NS;VXOT[&/1/@:^P
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M-\+M@&+,SH[YT7E^"S',K#!ZT?W/'?W+VCK-9/@M@,=CBU8AS%W$T_.PIRU
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M9HP)@"D@,R48>$_[N QL=<C1F" ZVG!I,<T2^ (1,W>(B:KED('ZU'[!1Z@
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M9"TR,#(T,#$S,%]L86(N>&UL4$L! A0#%     @ NW8^6)3K.&JJ!0  1C0
M !4              ( !4!P  '5T;60M,C R-# Q,S!?<')E+GAM;%!+ 0(4
M Q0    ( +MV/EB&A7,<73,  ,N; 0 /              "  2TB  !U=&UD
A7V5X.3EZ,2YH=&U02P4&      8 !@"$ 0  MU4

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>utmd-20240130_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="utmd-20240130.xsd" xlink:type="simple"/>
    <context id="D240130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2024-01-30</startDate>
            <endDate>2024-01-30</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="D240130" id="fact1">0000706698</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="D240130" id="fact2">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="D240130" id="ixv-349">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="D240130" id="ixv-350">2024-01-30</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="D240130" id="ixv-351">UTAH MEDICAL PRODUCTS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="D240130" id="ixv-352">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="D240130" id="ixv-353">000-12575</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="D240130" id="ixv-354">87-0342734</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="D240130" id="ixv-355">7043 South 300 West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="D240130" id="ixv-356">Midvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="D240130" id="ixv-357">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="D240130" id="ixv-358">84047</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="D240130" id="ixv-359">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="D240130" id="ixv-360">566-1200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="D240130" id="ixv-361">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="D240130" id="ixv-362">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="D240130" id="ixv-363">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="D240130" id="ixv-364">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="D240130" id="ixv-365">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
